JCR Pharmaceuticals Returns to Profit but Warns of Earnings Drop Amid Sales Growth

JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) just unveiled an announcement.

JCR Pharmaceuticals reported a strong turnaround for the fiscal year ended March 31, 2026, with consolidated net sales rising 21.9% to ¥40.3 billion and a swing back to profitability, posting ¥2.18 billion in profit attributable to owners of parent after a loss a year earlier. Margins remained modest, with operating profit of ¥555 million and an equity ratio of 42.9%, while operating cash flow was slightly negative but supported by positive financing cash flows and steady cash on hand.

The company kept its annual dividend flat at ¥20 per share despite the profit recovery, implying a high payout ratio, and forecasts further top-line growth in the year to March 2027, guiding for 13.3% higher sales to ¥45.7 billion. However, it projects a sharp decline in profit attributable to owners to ¥200 million and earnings per share of ¥1.64, signaling that higher revenue will be offset by rising costs or strategic investments, a dynamic that investors and other stakeholders will watch closely for its impact on future profitability and capital allocation.

The most recent analyst rating on (JP:4552) stock is a Buy with a Yen900.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.

More about JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange that develops and manufactures pharmaceutical products. The company focuses on ethical pharmaceuticals and specialty treatments, operating both as a research-driven drug developer and a commercial manufacturer in domestic and overseas markets.

Average Trading Volume: 551,901

Technical Sentiment Signal: Strong Sell

Current Market Cap: Yen69.05B

For detailed information about 4552 stock, go to TipRanks’ Stock Analysis page.